Cosmo Bio CoTSE:3386 -0.55%73 EV-to-FCF is 14.39 as of Jul. 09, 2026, which is 140% above its 10-year median of 5.99. GuruFocus rates TSE:3386 with a GF Score™ of 73/100 and a GF Value™ of 円1,246.90 (Fairly Valued). The stock has 4 warning signs investors should review. Among 98 Medical Diagnostics & Research companies, Cosmo Bio Co ranks better than 67.35% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cosmo Bio Co's Enterprise Value is 円4,519 Mil.
Cosmo Bio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was 円314 Mil. Therefore, Cosmo Bio Co's EV-to-FCF for today is 14.39.
The historical rank and industry rank for Cosmo Bio Co's EV-to-FCF or its related term are showing as below:
TSE:3386'
s EV-to-FCF Range Over the Past 10 Years
Min: -183.99 Med: 5.99 Max: 18.92
Current: 14.46
During the past 13 years, the highest EV-to-FCF of Cosmo Bio Co was 18.92. The lowest was -183.99. And the median was 5.99.
TSE:3386's EV-to-FCF is ranked better than 67.35% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.465
vs TSE:3386: 14.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cosmo Bio Co's PE Ratio (TTM) for today is calculated as:
Cosmo Bio Co's share price for today is 円1262.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Bio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was 円59.260.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cosmo Bio Co EV-to-FCF Related Terms
Cosmo Bio Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Cosmo Bio Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Cosmo Bio Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Bio Co EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cosmo Bio Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cosmo Bio Co's EV-to-FCF falls into.
Cosmo Bio Co's current Enterprise Value is 円4,519 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Bio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was 円314 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Bio Co (TSE:3386) has a EV-to-FCF of 14.39 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cosmo Bio Co and its competitors. This is 140% above median its historical median of 5.99. According to the industry distribution chart, Cosmo Bio Co ranks #32 out of 98 companies in the Medical Diagnostics & Research industry, placing it in the top 32.7%.
Is Cosmo Bio Co's EV-to-FCF too high?
Cosmo Bio Co's current EV-to-FCF of 14.39 is 140% above median its 10-year median of 5.99. The Medical Diagnostics & Research industry median EV-to-FCF is 22.47. Cosmo Bio Co's value of 14.39 is 35.9% below this industry median. Based on the distribution chart, Cosmo Bio Co ranks #32 out of 98 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Cosmo Bio Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosmo Bio Co's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cosmo Bio Co ranks #32 out of 98 companies for EV-to-FCF. This puts Cosmo Bio Co in the upper half of its industry. The industry median EV-to-FCF is 22.47. Cosmo Bio Co's value of 14.39 is 35.9% below this benchmark. While the company's 10-year median is 5.99 vs. the industry median of 22.47, Cosmo Bio Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.47, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo Bio Co's current EV-to-FCF of 14.39 is 35.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cosmo Bio Co and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo Bio Co's current EV-to-FCF is 14.39, which is 140% above median its own 10-year median of 5.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo Bio Co stock overvalued right now?
Based on GuruFocus' analysis, Cosmo Bio Co (TSE:3386) is currently considered Fairly Valued. The stock's GF Value™ is 円1,246.90, compared to a current price of 円1,262.00 — trading 1.2% above its estimated fair value. The current EV-to-FCF is 14.39, which is 140% above median its 10-year median of 5.99 and 35.9% below the Medical Diagnostics & Research industry median of 22.47. Cosmo Bio Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cosmo Bio Co (TSE:3386), the current EV-to-FCF is 14.39 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo Bio Co (TSE:3386) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo Bio Co stock appears to be overvalued.
The current stock price of 円1,262.00 is trading 1.2% above its estimated GF Value™ of 円1,246.90.
GuruFocus considers Cosmo Bio Co to be Fairly Valued.
Key valuation signals for TSE:3386:
EV-to-FCF: 14.39 (140% above median its 10-year median of 5.99)
GF Value™: 円1,246.90 vs. price of 円1,262.00 (1.2% above fair value)
Industry Position: 35.9% below the Medical Diagnostics & Research median (#32 of 98)
No single metric tells the full story. See the TSE:3386 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo Bio Co Ltd is a diagnostic and research company based in Japan. The business of the company includes the purchase of reagents, instruments, and clinical test drugs for research in life science and domestic sales.
73GF Score
Get the complete analysis for TSE:3386
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3386 has been successfully added to your 
